CTLA4

3

Review clinical trials related to CTLA4. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Novel Genetic Disorders of the Immune System

Background: \- The immune system helps the body fight infection and disease. People with immune system problems can get infections, blood disorders, and other health problems. Researchers want to learn more about the immune system, like what causes it to not work properly. Objectives: \- To evaluate people with certain types of immune system disorders. Eligibility: \- Adults and children with an immune disorder or symptoms of one, and their relatives. Some disorders are not included in this study. Design: * Researchers will review participants medical records. * Participants may mail in a blood or saliva sample, or be evaluated at the clinic. At the clinic, they may have a medical history, physical exam, blood tests, and imaging scans (with dye given through a needle in the arm). They may have genetic testing done on a sample of blood, saliva, hair, or nail clipping. * Participants may choose to have a skin biopsy. Up to 2 skin samples will be taken from their arm, back, or other area. A biopsy punch is inserted into the skin and rotated. A small circle of skin is removed. * Participants 10 and older may also choose to have leukapheresis. Blood is taken through a needle in one arm. It passes through a machine that separates the white blood cells. The rest of the blood is returned by needle in the other arm. * Researchers may recommend medicines, but no treatments are being studied. * Participants may be invited to return for visits over several years. At those visits, they may repeat some or all of the above tests. Or they may mail in blood or other samples. They may also send medical records.

Participants needed: 500
Trial details
Age: 3-99Biological sex: AllType: ObservationalSponsor: National Institute of Allergy and Infectious Diseases (NIAID)Updated: Jun 18, 2026Locations: 1
Eligibility criteria

Patient and relatives aged 0-99 years old to include women who are pregnant or b... [+8]

Known genetic disorders that are already well characterized, such as severe comb... [+3]

Status: Recruiting

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.

Participants needed: 34
Trial details
Phase: Phase 1, Phase 2Age: 21-75Biological sex: AllType: InterventionalSponsor: Guangzhou Medical UniversityUpdated: May 18, 2025Locations: 2
Eligibility criteria

Histologically or cytologically confirmed diagnosis of solid tumors; Cerebrospin... [+2]

Any evidence of nervous system failure, including severe encephalopathy, grade 3... [+3]

Status: Recruiting

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18-85Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital of Guangzhou Medical UniversityUpdated: Jun 25, 2024Locations: 1
Eligibility criteria

Patients with advanced cancers that failed to current available therapies; [+4]

Had accepted gene therapy before; [+6]